Open Access

Getting real world and “hands on” in patients with elevated LDL-C and high risk features for atherosclerotic cardiovascular disease — Case management sessions.

Topic: Lipids
Sponsored by Sanofi US and Regeneron Pharmaceuticals

Congress Presentation

About the speaker

Professor Deepak Bhatt

Mount Sinai Hospital, New York (United States of America)
36 presentations
4 followers

4 more presentations in this session

Chairman’s welcome and introduction: the mandate for improving residual cardiovascular disease risk reduction in patients with adversely elevated LDL-C

Speaker: Professor D. Bhatt (New York, US)

Thumbnail

What do recent landmark, cardiovascular outcome trials evaluating PCSK9 inhibition in high risk patient populations teach us?

Speaker: Professor P. Steg (Paris, FR)

Thumbnail

Guidelines and the role of non-statin therapies for ASCVD reduction in high risk patients - Addressing statin intolerance and poor target LDL-C goal attainment

Speaker: Professor J. Jukema (Leiden, NL)

Thumbnail

Interactive question and answer session - PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease.

Speaker: Professor D. Bhatt (New York, US)

Thumbnail

Access the full session

PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease

Speakers: Professor D. Bhatt, Professor D. Bhatt, Professor P. Steg, Professor J. Jukema, Professor D. Bhatt
Thumbnail

About the event

Image

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb